SUBSCRIBERS
Takeda hikes outlook on cancer drug sales, Q3 profit jumps 60%
Published Thu, Feb 1, 2018 · 09:50 PM
Tokyo
TAKEDA Pharmaceutical Co Ltd said that its annual profit will outstrip a prior estimate and reach a six-year high, boosted by stronger sales of the cancer drug Velcade, after earlier reporting better-than-expected quarterly earnings.
Velcade is used to treat multiple myeloma, a type of blood cancer. A US court last year upheld Takeda's patent, giving …
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
France's Casino supermarket chain to axe up to 3,200 jobs
Prada outshines rivals with 16% revenue lift boosted by Miu Miu
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop